Drug updates and approvals: 2019 in review. Issue 12 (December 2019)

• Record Type: Journal Article
• Authors: Crump, Lauren Hartsell; Benfield, Miranda; Ramey, Caleb; Arcara, Ashley; Yang, Sebin; Brown, Jenna; Mospan, Geoffrey; Mospan, Cortney
• Is Part Of: Nurse practitioner. Volume 44:Issue 12(2019:Dec.)
• Publication Date: 2019-12
• Subjects: corticosteroid -- drug approvals -- FDA -- HIV -- multiple sclerosis -- narcolepsy -- new drugs -- obstructive sleep apnea -- osteoporosis -- postpartum depression -- psoriasis; Nursing -- Periodicals; Nurse practitioners -- Periodicals; 610.73
• DOI: 10.1097/01.NPR.0000605508.04187.b2
• Languages: English
• ISSNs: 0361-1817

Abstract

Abstract : Abstract: In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol (Duaklir Pressair); and siponimod (Mayzent). Abstract : In 2019, the FDA approved several new drugs for use in primary care. This article highlights the following new drugs: risankizumab-rzaa (Skyrizi); halobetasol and tazarotene (Duobrii); dolutegravir and lamivudine (Dovato); romosozumab-aqqg (Evenity); brexanolone (Zulresso); solriamfetol (Sunosi); aclidinium and formoterol(Duaklir Pressair); and siponimod (Mayzent).